Co.don AG is a biotechnology company specializing in the development, production, and distribution of cell-based pharmaceutical products for the regeneration of articular cartilage. The company's primary function is to innovate in the field of orthobiologics, offering advanced solutions for the treatment of cartilage ailments through its proprietary cell cultivation technology. Co.don AG significantly impacts the healthcare and pharmaceutical sectors by providing minimally invasive treatments that aim to improve patients' quality of life and reduce the need for surgical interventions. Headquartered in Teltow, Germany, the company is pivotal in addressing chronic joint conditions and contributes to the broader field of regenerative medicine. Its products are utilized in various hospitals and clinics, enhancing the company's role as a contributor to advanced medical therapies in Europe and beyond. Co.don AG's focus on biotechnological advancements positions it as a key player in the evolving landscape of medical treatments aimed at supporting patients with degenerative cartilage conditions.